Sarkar S, Pradhan A, Das S, Emdad L, Sarkar D, Pellecchia M, Fisher P. Novel therapy of prostate cancer employing a combination of viral-based immunotherapy and a small molecule BH3 mimetic. Oncoimmunology. 2015 September. (doi:10.1080/2162402X.2015.1078059) (Impact factor 6.3).

Rajput S, Puvvada N, Kumar BN, Sarkar S, Konar S, Bharti R, Dey G, Mazumdar A, Pathak A, Fisher PB, Mandal M. Overcoming Akt induced therapeutic resistance in breast cancer through siRNA and thymoquinone encapsulated multilamellar gold niosomes. Mol Pharm. 2015 Oct 27. [Epub ahead of print] PMID: 26505213. (Impact factor 4.4)

Dey KK, Sarkar S, Pal I, Das S, Dey G, Bharti R, Banik P, Ray JG, Maity S, Kulavi I, Mandal M. Mechanistic attributes of S100A7 (psoriasin) in resistance of anoikis resulting tumor progression in squamous cell carcinoma of the oral cavity. Cancer Cell Int. 2015 Oct 8;15: 74. (Impact factor 2.8)

Quinn BA, Dash R, Sarkar S, Azab B, Bhoopathi P, Das SK, Emdad L, Wei J, Pellecchia M, Sarkar D, Fisher PB. Pancreatic Cancer Combination Therapy Using a BH3 Mimetic and a Synthetic Tetracycline. Cancer Res. 2015 Jun 1; 75(11): 2305-2315. (Impact factor 9.3).

PuvvadaN, Rajput S, Kumar BN, Sarkar S, Konar S, Brunt KR, Rao R, Mazumdar A, Das, SK, Basu R, Fisher PB, Mandal M, Pathak A. Novel ZnO hollow-nanocarriers containing paclitaxel targeting folate-receptors in a malignant pH-microenvironment for effective monitoring and promoting breast tumor regression. Sci Rep. 2015 Jul 6; 5:11760.  (Impact factor 5.07)

Das P, Sarkar S, Mandal M, Sen R. Green surfactant of marine origin exerting a cytotoxic effect on cancer cell lines. RSC Adv. 2015 Jun 10; 5: 53086-53094. (Impact factor 3.9)

Sarkar S, Quinn BA, Shen X-N, Dash R, Das SK, Emdad L, Klibanov AL, Wang X-Y, Pellecchia M, Sarkar D, Fisher PB. Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic. Oncotarget 2015 Mach; 6(13): 10712-10727.  (Impact factor 6.63).

Sarkar S, Quinn BA, Shen X, Dent P, Das SK, Emdad L, Sarkar D, Fisher PB. Reversing translational suppression and induction of toxicity in pancreatic cancer cells using a chemoprevention gene therapy (CGT) approach. Mol Phramacol. 2015 Feb; 87(2):286-295. (Impact factor 4.5).

Kumar BN, Puvvada N, Rajput S, Sarkar S, Venkatesan P, Pal I, Dey G, Konar S, Mazumdar A, Kundu SC, Pathak A, Fisher PB, Mandal. M Sequential release of tamoxifen and diosgenin from hollow manganese ferrate nanocarriers for breast cancer treatment. J. Mater. Chem. B, 2015; 3: 90-101 (Impact factor 6.5).